Besides, recent data suggest that ALK rearrangements occur more frequently in younger NSCLC patients compared to older patients with lung cancer [44–47], whereas KRAS mutations appear to be less frequent in the younger patient cohort [44,45]. This evidence concerns the gene ALK and lung cancer.